Late Safety and Efficacy of a Zotarolimus-Eluting Stent Compared with a Paclitaxel-Eluting Stent in Patients with De Novo Coronary Lesions: Three-Year Follow-up from the ENDEAVOR IV Trial

被引：0

作者：

Leon, Martin B. ^{[1
]}

Mauri, Laura ^{[2
]}

O'Shaughnessy, Charles ^{[3
]}

Ovelie, Paul A. ^{[4
]}

McLaurin, Brent T. ^{[5
]}

Solomon, Stuart L. ^{[6
]}

Ball, Michael ^{[7
]}

Douglas, John S. ^{[8
]}

Cutlip, Donald E. ^{[9
]}

Kandzari, David E. ^{[10
]}

机构：

[1] Columbia Univ, Med Ctr, New York, NY USA

[2] Brigham & Womens Hosp, Harvard Clin Res Inst, Boston, MA 02115 USA

[3] Elyria Mem Hosp, Elyria, OH USA

[4] Lubbock Heart Hosp, Lubbock, TX USA

[5] Anderson Med Ctr, Anderson, SC USA

[6] Methodist Hosp, Houston, TX 77030 USA

[7] Heart Ctr Indiana, Indianapolis, IN USA

[8] Emory Univ Hosp, Atlanta, GA 30322 USA

[9] Harvard Cardiac Res Inst, Boston, MA USA

[10] Scripps Clin, La Jolla, CA USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2009年 / 104卷 / 6A期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：150D / 150D

页数：1

共 50 条

[1] The "Final" 5-Year Follow-Up From the ENDEAVOR IV Trial Comparing a Zotarolimus-Eluting Stent With a Paclitaxel-Eluting Stent
Kirtane, Ajay J.
Leon, Martin B.
Ball, Michael W.
Bajwa, Harpaul S.
Sketch, Michael H., Jr.
Coleman, Patrick S.
Stoler, Robert C.
Papadakos, Stylianos
Cutlip, Donald E.
Mauri, Laura
Kandzari, David E.
JACC-CARDIOVASCULAR INTERVENTIONS, 2013, 6 (04) : 325 - 333
[2] Late Safety Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions 2-Year Follow-Up From the ENDEAVOR IV Trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary, Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
Leon, Martin B.
Kandzari, David E.
Eisenstein, Eric L.
Anstrom, Kevin J.
Mauri, Laura
Cutlip, Donald E.
Nikolsky, Eugenia
O'Shaughnessy, Charles
Overlie, Paul A.
Kirtane, Ajay J.
McLaurin, Brent T.
Solomon, Stuart L.
Douglas, John S., Jr.
Popma, Jeffrey J.
JACC-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (12) : 1208 - 1218
[3] The "Final" Five-Year Follow-up front the ENDEAVOR IV Trial Comparing a Zotarolimus-Eluting Stent with a Paclitaxel-Eluting Stent
Leon, Martin B.
Kandzari, David E.
Mauri, Laura
Ball, Michael W.
Bajwa, Harpaul S.
Sketch, Michael H.
Coleman, Patrick S.
Stoler, Robert C.
Papadakos, Stylianos
Cutlip, Donald E.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (20) : B8 - B8
[4] Improved Late Clinical Safety With Zotarolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in Patients With De Novo Coronary Lesions 3-Year Follow-Up From the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) Trial
Leon, Martin B.
Nikolsky, Eugenia
Cutlip, Donald E.
Mauri, Laura
Liberman, Henry
Wilson, Hadley
Patterson, John
Moses, Jeffrey
Kandzari, David E.
JACC-CARDIOVASCULAR INTERVENTIONS, 2010, 3 (10) : 1043 - 1050
[5] A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions 12-Month Outcomes From the ENDEAVOR IV Trial
Leon, Martin B.
Mauri, Laura
Popma, Jeffrey J.
Cutlip, Donald E.
Nikolsky, Eugenia
O'Shaughnessy, Charles
Overlie, Paul A.
McLaurin, Brent T.
Solomon, Stuart L.
Douglas, John S., Jr.
Ball, Michael W.
Caputo, Ronald P.
Jain, Ash
Tolleson, Thaddeus R.
Reen, Bernard M., III
Kirtane, Ajay J.
Fitzgerald, Peter J.
Thompson, Kweli
Kandzari, David E.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (06) : 543 - 554
[6] Comparison of the Efficacy and Safety of the Zotarolimus-Eluting Stent versus Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent for Coronary Lesions
Bergmann, M. W.
HERZ, 2009, 34 (04) : 330 - 330
[7] Comparison of Zotarolimus-Eluting Stents With Sirolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization The ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) Randomized Trial
Park, Duk-Woo
Kim, Young-Hak
Yun, Sung-Cheol
Kang, Soo-Jin
Lee, Seung-Whan
Lee, Cheol-Whan
Park, Seong-Wook
Seong, In-Whan
Lee, Jae-Hwan
Tahk, Seung-Jea
Jeong, Myung-Ho
Jang, Yangsoo
Cheong, Sang-Sig
Yang, Joo-Young
Lim, Do-Sun
Seung, Ki-Bae
Chae, Jei-Keon
Hur, Seung-Ho
Lee, Sang-Gon
Yoon, Junghan
Lee, Nae-Hee
Choi, Young-Jin
Kim, Hyun-Sook
Kim, Kee-Sik
Kim, Hyo-Soo
Hong, Taeg-Jong
Park, Hun-Sik
Park, Seung-Jung
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (15) : 1187 - 1195
[8] Comparison of Vascular Response to Zotarolimus-Eluting Stent Versus Paclitaxel-Eluting Stent Implantation: IVUS Results From the ENDEAVOR IV Trial
Waseda, Katsuhisa
Miyazawa, Akiyoshi
Hasegawa, Takao
Tsujino, Ichizo
Sakurai, Ryota
Ako, Junyo
Yock, Paul G.
Honda, Yasuhiro
Kandzari, David E.
Leon, Martin B.
Fitzgerald, Peter J.
AMERICAN JOURNAL OF CARDIOLOGY, 2008, 102 (8A): : 146I - 146I
[9] A randomized comparison of a zotarolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease
Woehrle, J.
HERZ, 2007, 32 (08) : 672 - 672
[10] A Randomized Comparison of a Zotarolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease
Buellesfeld, L.
HERZ, 2009, 34 (02) : 166 - 166

← 1 2 3 4 5 →